Consensus guidelines for the management and treatment of neuroendocrine tumors.
Pamela L. Kunz,Diane Reidy-Lagunes,Lowell Anthony,Erin M. Bertino,Kari Brendtro,Jennifer A. Chan,Herbert Chen,Robert T. Jensen,Michelle K. Kim,David S. Klimstra,Matthew H. Kulke,Eric H. Liu,David C. Metz,Alexandria T. Phan,Rebecca S. Sippel,Jonathan R. Strosberg,James C. Yao +16 more
Reads0
Chats0
TLDR
A set of consensus tables intended to complement the North American Neuroendocrine Tumor Society guidelines and serve as a quick, accessible reference for the practicing physician are presented.Abstract:
Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician.read more
Citations
More filters
Journal ArticleDOI
Gastroenteropancreatic high-grade neuroendocrine carcinoma.
TL;DR: Platinum‐based chemotherapy may not be the optimal treatment for patients who have GEP‐NEC with a moderately high proliferation rate, and patients with such tumors or with well differentiated morphology had better survival than patients who had tumors with poorly differentiated morphology or a higher Ki‐67 index.
Journal ArticleDOI
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.
Jonathan R. Strosberg,Thorvardur R. Halfdanarson,Andrew M. Bellizzi,Jennifer A. Chan,Joseph S. Dillon,Anthony P. Heaney,Pamela L. Kunz,Thomas M. O'Dorisio,Riad Salem,Eva Segelov,James R. Howe,Rodney F. Pommier,Kari Brendtro,Mohammad Bashir,Simron Singh,Michael C. Soulen,Laura H. Tang,Jerome S. Zacks,James C. Yao,Emily K. Bergsland +19 more
TL;DR: The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article and surgical guidelines are described in a companion article.
Journal ArticleDOI
The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.
James R. Howe,Kenneth Cardona,Douglas L. Fraker,Electron Kebebew,Brian R. Untch,Yi-Zarn Wang,Calvin Law,Eric Liu,Michelle K. Kim,Yusuf Menda,Brian Morse,Emily K. Bergsland,Jonathan R. Strosberg,Eric K. Nakakura,Rodney F. Pommier +14 more
TL;DR: A consensus conference was held assembling experts in the field to review and discuss the available literature and patterns of practice pertaining to specific management issues regarding the management of small bowel neuroendocrine tumors.
Journal ArticleDOI
Consensus on biomarkers for neuroendocrine tumour disease
Kjell Öberg,Irvin M. Modlin,Wouter W. de Herder,Marianne Pavel,David S. Klimstra,Andrea Frilling,David C. Metz,Anthony P. Heaney,Dik J. Kwekkeboom,Jonathan R. Strosberg,Tim Meyer,Steven F. Moss,Kay Washington,Edward M. Wolin,Eric Liu,James R. Goldenring +15 more
TL;DR: A multinational consensus meeting of multidisciplinary experts in neuroendocrine tumours assessed the use of current biomarkers and defined the perquisites for novel biomarkers via the Delphi method and concluded that circulating multianalyte biomarkers provide the highest sensitivity and specificity necessary for minimum disease detection.
Journal ArticleDOI
The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors
James R. Howe,Nipun B. Merchant,Claudius Conrad,Xavier M. Keutgen,Julie Hallet,Jeffrey A. Drebin,Rebecca M. Minter,Terry C. Lairmore,Jennifer F. Tseng,Herbert J. Zeh,Steven K. Libutti,Gagandeep Singh,Jeffrey E. Lee,Thomas A. Hope,Michelle K. Kim,Yusuf Menda,Thorvardur R. Halfdanarson,Jennifer A. Chan,Rodney F. Pommier +18 more
TL;DR: The group reviewed a series of questions of specific interest to surgeons taking care of patients with pancreatic neuroendocrine tumors, and for each, the available literature was reviewed.
References
More filters
Journal ArticleDOI
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao,Manisha H. Shah,Tetsuhide Ito,Catherine Lombard Bohas,Edward M. Wolin,Eric Van Cutsem,Timothy J. Hobday,Takuji Okusaka,Jaume Capdevila,Elisabeth G.E. de Vries,Paola Tomassetti,Marianne Pavel,Sakina Hoosen,Tomas Haas,Jeremie Lincy,David Lebwohl,Kjell Öberg +16 more
TL;DR: Everolimus, as compared with placebo, significantly prolonged progression-free survival among patients with progressive advanced pancreatic neuroendocrine tumors and was associated with a low rate of severe adverse events.
Journal ArticleDOI
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Eric Raymond,Laetitia Dahan,Jean-Luc Raoul,Yung-Jue Bang,Ivan Borbath,Catherine Lombard-Bohas,Juan W. Valle,Peter Metrakos,Denis Smith,Aaron I. Vinik,Jen-Shi Chen,Dieter Hörsch,Pascal Hammel,Bertram Wiedenmann,Eric Van Cutsem,Shem Patyna,Dongrui Ray Lu,C. Blanckmeister,Richard C. Chao,Philippe Ruszniewski +19 more
TL;DR: Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors.
Journal ArticleDOI
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke,Carmen Schade-Brittinger,Klaus-Jochen Klose,Peter Barth,M. Wied,Christina Mayer,Behnaz Aminossadati,Ulrich-Frank Pape,Jan Harder,Christian N. Arnold,Thomas M. Gress,Rudolf Arnold +11 more
TL;DR: Octreotide LAR demonstrates substantial tumor control and shows a more favorable antiproliferative response than placebo as two-thirds of patients treated with octreotide ARL achieved stable disease at 6 mos, and patients treatment-naïve patients with histologically confirmed locally inoperable or metastasized well-differentiated NETs had a 66% risk reduction of tumor progression.
Journal ArticleDOI
Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
Dik J. Kwekkeboom,Wouter W. de Herder,Boen L. Kam,Casper H.J. van Eijck,Martijn van Essen,P. P. M. Kooij,Richard A Feelders,Maarten O. van Aken,Eric P. Krenning +8 more
TL;DR: Treatment with peptide receptor radionuclide therapy with the radiolabeled somatostatin analog [(177)Lu-DOTA(0),Tyr(3)]octreotate has few adverse effects and compares favorably to the limited number of alternative treatment modalities.
Journal ArticleDOI
The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems.
TL;DR: Issues in the pathologic assessment of NETs that are common among primaries of different sites are examined and the distinction of well-differentiated from poorly differentiated NETs and the significance of proliferative rate in prognostic assessment are examined.
Related Papers (5)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Eric Raymond,Laetitia Dahan,Jean-Luc Raoul,Yung-Jue Bang,Ivan Borbath,Catherine Lombard-Bohas,Juan W. Valle,Peter Metrakos,Denis Smith,Aaron I. Vinik,Jen-Shi Chen,Dieter Hörsch,Pascal Hammel,Bertram Wiedenmann,Eric Van Cutsem,Shem Patyna,Dongrui Ray Lu,C. Blanckmeister,Richard C. Chao,Philippe Ruszniewski +19 more